Management of stroke in patients on antithrombotic therapy: Practical issues in the era of direct oral anticoagulants.

Rev Neurol (Paris)

Hôpital Pellegrin, CHU de Bordeaux, Unité Neurovasculaire, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France.

Published: March 2022

Antithrombotic drugs (ADs) are the mainstay of secondary prevention of thrombotic vascular diseases. Management of patients under long-term treatment with ADs admitted for acute cerebrovascular disease, either ischemic stroke (IS) or intracerebral hemorrhage (ICH), has become a frequent situation that might influence decision-making processes from diagnosis to therapeutic strategies. The aim of this review is to summarize current data from the literature to help clinicians in their decisions for stroke care in patients taking ADs. While a large body of data have made it possible to codify the management of patients presenting IS or ICH under antiplatelet drugs and vitamin K antagonists, the increasing use of direct oral anticoagulants (DOAs) and future development of new antiplatelet drugs raise new problems. Development of rapid assessment tools measuring specific biological activity and reversion agents dedicated to each class of DOAs should make it possible to optimize individual therapeutic strategies. This review highlights the main steps of IS and ICH management from early identification of ADs, and use of dedicated biological assays, to the stepwise strategy to apply revascularization or reversal therapies and finally the resumption of ADs with a focus on individual clinical and radiological characteristics for more personalized care.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2021.07.021DOI Listing

Publication Analysis

Top Keywords

direct oral
8
oral anticoagulants
8
management patients
8
therapeutic strategies
8
antiplatelet drugs
8
ads
5
management
4
management stroke
4
patients
4
stroke patients
4

Similar Publications

How Should We Use Hyaluronidase for Dissolving Hyaluronic Acid Fillers?

J Cosmet Dermatol

January 2025

Division in Anatomy and Developmental Biology, Department of Oral Biology, Human Identification Research Institute, BK21 FOUR Project, Yonsei University College of Dentistry, Seoul, Korea.

Background: Hyaluronic acid (HA) fillers are commonly used in esthetic medicine for facial contouring and rejuvenation. However, complications such as overcorrection, vascular occlusion, and irregular filler distribution necessitate the use of hyaluronidase to dissolve the fillers. This study aimed to evaluate the efficacy of hyaluronidase in degrading different types of HA fillers and provide clinical guidelines for its use based on filler type, dosage, and application techniques.

View Article and Find Full Text PDF

Recent advances in teaching-learning methodologies of the Ayurveda education system.

J Educ Health Promot

November 2024

Department of Dravyaguna, Mahatma Gandhi Ayurved College, Hospital and Research Centre, Salod (H), Datta Meghe Institute of Higher Education and Research (Deemed to be University), Wardha, Maharashtra, India.

Teaching and learning are two sides of the same coin. Ayurveda, the ancient system of medicine that originated in India, has a long history of teaching and learning methods. In the early days, Ayurvedic knowledge was primarily transmitted through oral tradition, with teachers passing down their knowledge to students through direct communication.

View Article and Find Full Text PDF

Eupalinolide B inhibits periodontitis development by targeting ubiquitin conjugating enzyme UBE2D3.

MedComm (2020)

January 2025

Department of Urology, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology Shenzhen China.

Periodontitis is a chronic periodontal inflammatory disease caused by periodontal pathogens commonly seen in adults. Eupalinolide B (EB) is a sesquiterpenoid natural product extracted from Eupatorium lindleyanum and has been reported as a potential drug for cancers and immune disorders. Here, we explored the ameliorative effects and underlying molecular mechanism of EB on periodontitis for the first time.

View Article and Find Full Text PDF

Obstetric penicillin allergy evaluations.

J Allergy Clin Immunol Glob

February 2025

Division of Allergy, Immunology, Rheumatology, Rochester Regional Health.

Background: Penicillin allergy is reported in 5% to 15% of the world population, with 3% to 10% of pregnant women reporting the same. However, more than 90% of these patients can tolerate penicillin after appropriate evaluation. Penicillin is indicated for various issues that arise in pregnancy, and a history of allergy can have negative individual and public health consequences.

View Article and Find Full Text PDF

Acquired factor V inhibitor in a case of pediatric venous thrombosis.

Res Pract Thromb Haemost

January 2025

Department of Pediatric Hematology, Innovative Hematology, Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.

Background: The development of acquired factor (F)V with inhibitor (AFVwI) is rare, resulting mainly in bleeding complications, although sporadic cases of thrombosis in adults have been reported.

Key Clinical Question: How do you diagnose and manage a pediatric case of acute deep venous thrombosis associated with the concurrent finding of AFVwI?

Clinical Approach: A 13-year-old female with Crohn's Disease and May-Thurner anatomy developed extensive deep venous thrombosis of the left lower extremity, complicated by the finding of AFVwI, discovered during the evaluation of a prolonged prothrombin time and a low FV activity. Anticoagulation was initiated with low-molecular-weight heparin followed by a direct oral anticoagulant, rivaroxaban, without any complications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!